Genmab fortsätter klinisk studie

Amerikanska FDA har nu get klartecken för det danska bolaget att gå vidare med kliniska studier av ett cancerpreparat.

By Totta Kasemo

July 21, 2009 12:00 AM

FDA, Food and Drug Administration,

har get Genmab tillstånd att gå vidare med sina fas II-studier på preparatet zalutumumab.

Studien görs

som en så kallad Investigational New Drug application. Patienrekryteringen av personer med obotlig huvud- och nackcancer kommer nu att påbörjas. I en fas I/II kommer också preparatet att studeras i kombination med kemoterapi.

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.